Search

Author/Creator Roblin, X.

21. Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti‐tumour necrosis factor. Issue 8 (15th February 2018)

Authors:
Ben‐Horin, S.; Ungar, B.; Kopylov, U.; Lahat, A.; Yavzori, M.; Fudim, E.; Picard, O.; Peled, Y.; Eliakim, R.; Del Tedesco, E.; Paul, S.; Roblin, X.
Journal:
Alimentary pharmacology & therapeutics
Issue:
Volume 47:Issue 8(2018)
Page Start:
1117
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

22. The impact of cytomegalovirus reactivation and its treatment on the course of inflammatory bowel disease. Issue 7 (9th February 2014)

Authors:
Delvincourt, M.; Lopez, A.; Pillet, S.; Bourrier, A.; Seksik, P.; Cosnes, J.; Carrat, F.; Gozlan, J.; Beaugerie, L.; Roblin, X.; Peyrin‐Biroulet, L.; Sokol, H.
Journal:
Alimentary pharmacology & therapeutics
Issue:
Volume 39:Issue 7(2014)
Page Start:
712
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗